search
Back to results

A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis (OptiRiMoxTB)

Primary Purpose

Tuberculosis, Human Immunodeficiency Virus

Status
Recruiting
Phase
Phase 3
Locations
Tanzania
Study Type
Interventional
Intervention
Optimised rifamycin
Sponsored by
Stellah Mpagama
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tuberculosis focused on measuring TB/HIV, Phase III, Randomised

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Each patient must meet all the following inclusion criteria prior to enrolment into the trial:

    1. The patient has given fully informed, signed written or witnessed oral informed consent for study participation prior to all trial-related procedures, including HIV testing if HIV status is not known.
    2. The patient has a diagnosis of pulmonary TB established by Xpert MTB/RIF® result which confirms "low" "medium" or "high" level detection of M tuberculosis and does not detect rifampicin resistance.

      1. If the patient has been referred from a clinic at which the pre-screening clinical diagnostic test for TB was an Xpert MTB/RIF® assay done at the trial laboratory, and the full read-out of that result is available, the test does not need to repeated to confirm eligibility.
      2. If the patient has been referred from a clinic at which the pre-screening clinical diagnostic test for TB was an Xpert MTB/RIF® assay done at a non-trial laboratory, but the full read-out of that result is available, the test does not need to repeated to confirm eligibility.
      3. If the patient has been referred to the study from a clinic from which the full pre-screening clinical diagnostic Xpert MTB/RIF® test result is unavailable, a repeat Xpert MTB/RIF® assay should be performed by the study laboratory to confirm eligibility before recruitment.
    3. The patient should be aged ≥ 18 years on the day of providing informed consent.
    4. The patient has a body weight in light clothing and without shoes of at least 35kg.
    5. Female patients of child-bearing potential must have a negative urine or serum pregnancy test ≤ 7 days prior to screening, and consent to practice an effective method of contraception until completion of therapy.
    6. The patient must have a verifiable residence location and telephone number that is accessible if necessary for contact during follow-up.

Exclusion Criteria:

  • Patients for whom one of the following criteria is met will be excluded from the trial:

    1. There is concern about any circumstances that raise concern about free, informed consent to study participation.
    2. The patient's pre-screening or screening Xpert MTB/RIF® assay result is "negative","trace", or "very low" positive.
    3. At least one M tuberculosis isolate, either cultured or detected through molecular assays from sputum obtained from the patient prior to treatment initiation is found to be resistant to one or more of: rifampicin, isoniazid, pyrazinamide, ethambutol, or fluoroquinolones (late exclusion).
    4. The patient is in poor general condition where delay in treatment cannot be tolerated, or death within three months is likely, as assessed by the investigator.
    5. The patient had a nose/throat swab which was positive for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2), on Polymerase Chain Reaction (PCR) or a rapid diagnostic test ≤ 14 days preceding study recruitment.
    6. The patient is pregnant or breast-feeding (female patients only).
    7. The patient is unable to take oral medications.
    8. The patient has received any investigational drug in the past three months.
    9. The patient has received more than five days of treatment directed against active tuberculosis ≤ 6 months preceding initiation of study drugs.
    10. The patient has known intolerance to any of the study drugs, or conditions for which they are contra-indicated.
    11. The patient is unwilling, or unable to adhere to requirements regarding restricted use of other medications during the study. Restricted medications will include medications which prolong the QTc interval, and CYP450 inhibitors or inducers.
    12. The patient is due to initiate, or requires continuation of, non-efavirenz, non-dolutegravir-based anti-retroviral therapy for HIV infection.
    13. The patient has decompensated liver disease and/or aminotransaminases >3x upper limit of normal (ULN), serum total bilirubin level >1.5x ULN or serum/plasma creatinine level >x2 ULN.
    14. The patient has a baseline QTc interval of >450ms.
    15. The patient is being, or about to be, treated for malaria.
    16. The patient has other medical conditions that, in the investigator's judgement, make study participation not in the individual's best interest.

Sites / Locations

  • Kibong'oto Infectious Diseases HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

No Intervention

Experimental

Experimental

Arm Label

No intervention

Experimental Arm 1

Experimental Arm 2

Arm Description

Standard of care according to the National TB Programmes which is a weight-banded rifampicin, isoniazid, pyrazinamide, and ethambutol for weeks 0-8 followed by rifampicin and isoniazid for weeks 9-26.

Optimised dose of rifampicin. The rifampicin 35mg/kg alongside standard weight-banded doses of isoniazid, pyrazinamide, and ethambutol, once daily

Optimised dose of rifampicin and moxifloxacin. The rifampicin 35mg/kg and moxifloxacin 400mg alongside standard weight-banded doses of isoniazid and pyrazinamide, once daily.

Outcomes

Primary Outcome Measures

Bacteriological cure, absence of either TB treatment failure or relapse
Treatment failure, defined as submitting two sputum samples with positive culture for M tuberculosis on different visits, when the first of these samples was collected at or after two weeks prior to the scheduled end of treatment. TB relapse, defined as submitting two sputum samples with positive culture for M tuberculosis on different visits, when the first of these samples was collected after completion of scheduled TB therapy and where at least one of the M tuberculosis isolates is genetically similar to the baseline strain.
Proportional of adverse events (AE) of grade 3 severity or higher
The severity of all AEs will be classified according to the U.S. National Institutes of Health Common Terminology Criteria for Adverse Events 5.0 (CTCAE).

Secondary Outcome Measures

Proportional of clinically significant adverse events related to the intervention
Treatment discontinuation or interruption related to AE
Clinical improvement of TB symptoms
Clinical response of TB symptoms as measured by questionnaire
Clinical improvement of body mass index (BMI)
Increase of BMI as measured by the ratio of weight (kg) and height squared in metres squared
Clinical improvement of participant reported health status
Increase of participant reported health status as measured by questionnaire

Full Information

First Posted
October 6, 2022
Last Updated
August 23, 2023
Sponsor
Stellah Mpagama
Collaborators
University of St Andrews, Radboud University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT05575518
Brief Title
A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis
Acronym
OptiRiMoxTB
Official Title
A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 11, 2023 (Actual)
Primary Completion Date
December 31, 2025 (Anticipated)
Study Completion Date
March 31, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Stellah Mpagama
Collaborators
University of St Andrews, Radboud University Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Tuberculosis (TB) remains a major global public health problem, particularly in low- and middle-income countries (LMICs) in Africa, Asia, and Eastern Europe. Approximately 10 million people fall sick with TB, causing up to 2 million deaths, worldwide per year. Considerable progress was made in TB control from 1990-2015, motivating the World Health Organization (WHO) to launch an ambitious EndTB strategy. However, the effect of the ongoing Coronavirus Disease 2019 (Covid-19) pandemic has been devastating and the last two years have seen the first year-on-year increases (of 5.6%) in TB mortality since 2005 . In order to regain lost ground, and re-establish progress towards elimination of TB, innovation is needed in all aspects of TB control, including development of shorter treatment regimens for drug susceptible (DS) and multi-drug resistant / rifampicin resistant (MDR/RR) forms of the disease. This protocol seeks to conduct the TB clinical trial combining the 8-methoxyfluroquinolone and optimised dose of rifamycing to address two questions. The first is to confirm the non-inferiority of a four-month optimised dose rifamycin and moxifloxacin-based regimen amongst African TB patient populations with high rates of co-incident HIV. Secondly, we seek to establish that the rifamycin of choice in potent 4-month anti-TB treatments could be rifampicin as this will be more rapidly up-scalable for public health impact.
Detailed Description
The study objectives of this clinical trial are Primary effectiveness objective: To evaluate whether one or both of two experimental regimens based on optimised dose rifampicin with or without moxifloxacin and given for 16 weeks are non-inferior to standard treatment for drug-susceptible tuberculosis given for 26 weeks, as assessed by patient survival, free of tuberculosis 12 months after initiation of therapy. Primary safety objective: To evaluate whether one or both of two experimental regimens based on optimised dose rifampicin with or without moxifloxacin and given for 16 weeks are as safe and tolerable as standard treatment for drug-susceptible tuberculosis given for 26 weeks, as assessed by the frequency of Adverse Events (AEs) of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 severity or higher. Participants will be individuals with bacteriological confirmed pulmonary TB aged 18 years or above, with or without HIV co-infection in Gabon, Malawi, Mozambique and Tanzania. The trial sites are also established members of the PanACEA / SimpliciTB group including the Centre de Recherches Médicales de Lambaréné (CERMEL)-Gabon, the Helse Nord Tuberculosis Initiative (HNTI) at Kamuzu University of Health Sciences (KUHES)-Malawi and the Polana Caniço Health Research and Training Center (CISPOC) at the Instituto Nacional de Saúde (INS)-Mozambique and the Kibong'oto Infectious Diseases Hospital-Tanzania.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tuberculosis, Human Immunodeficiency Virus
Keywords
TB/HIV, Phase III, Randomised

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
414 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
No intervention
Arm Type
No Intervention
Arm Description
Standard of care according to the National TB Programmes which is a weight-banded rifampicin, isoniazid, pyrazinamide, and ethambutol for weeks 0-8 followed by rifampicin and isoniazid for weeks 9-26.
Arm Title
Experimental Arm 1
Arm Type
Experimental
Arm Description
Optimised dose of rifampicin. The rifampicin 35mg/kg alongside standard weight-banded doses of isoniazid, pyrazinamide, and ethambutol, once daily
Arm Title
Experimental Arm 2
Arm Type
Experimental
Arm Description
Optimised dose of rifampicin and moxifloxacin. The rifampicin 35mg/kg and moxifloxacin 400mg alongside standard weight-banded doses of isoniazid and pyrazinamide, once daily.
Intervention Type
Drug
Intervention Name(s)
Optimised rifamycin
Other Intervention Name(s)
8-methoxy-fluoroquinolone
Intervention Description
optimised dose rifampicin with or without moxifloxacin
Primary Outcome Measure Information:
Title
Bacteriological cure, absence of either TB treatment failure or relapse
Description
Treatment failure, defined as submitting two sputum samples with positive culture for M tuberculosis on different visits, when the first of these samples was collected at or after two weeks prior to the scheduled end of treatment. TB relapse, defined as submitting two sputum samples with positive culture for M tuberculosis on different visits, when the first of these samples was collected after completion of scheduled TB therapy and where at least one of the M tuberculosis isolates is genetically similar to the baseline strain.
Time Frame
Participant survival, free of tuberculosis 12 months after randomisation
Title
Proportional of adverse events (AE) of grade 3 severity or higher
Description
The severity of all AEs will be classified according to the U.S. National Institutes of Health Common Terminology Criteria for Adverse Events 5.0 (CTCAE).
Time Frame
4 or 6 months of treatment
Secondary Outcome Measure Information:
Title
Proportional of clinically significant adverse events related to the intervention
Description
Treatment discontinuation or interruption related to AE
Time Frame
4 or 6 months of treatment
Title
Clinical improvement of TB symptoms
Description
Clinical response of TB symptoms as measured by questionnaire
Time Frame
12 month after randomisation
Title
Clinical improvement of body mass index (BMI)
Description
Increase of BMI as measured by the ratio of weight (kg) and height squared in metres squared
Time Frame
12 month after randomisation
Title
Clinical improvement of participant reported health status
Description
Increase of participant reported health status as measured by questionnaire
Time Frame
12 month after randomisation
Other Pre-specified Outcome Measures:
Title
Participant survival free of TB
Description
Recurrent of symptoms and bacteriological confirmation of TB
Time Frame
12 months after completing TB treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Each patient must meet all the following inclusion criteria prior to enrolment into the trial: The patient has given fully informed, signed written or witnessed oral informed consent for study participation prior to all trial-related procedures, including HIV testing if HIV status is not known. The patient has a diagnosis of pulmonary TB established by Xpert MTB/RIF® result which confirms "low" "medium" or "high" level detection of M tuberculosis and does not detect rifampicin resistance. If the patient has been referred from a clinic at which the pre-screening clinical diagnostic test for TB was an Xpert MTB/RIF® assay done at the trial laboratory, and the full read-out of that result is available, the test does not need to repeated to confirm eligibility. If the patient has been referred from a clinic at which the pre-screening clinical diagnostic test for TB was an Xpert MTB/RIF® assay done at a non-trial laboratory, but the full read-out of that result is available, the test does not need to repeated to confirm eligibility. If the patient has been referred to the study from a clinic from which the full pre-screening clinical diagnostic Xpert MTB/RIF® test result is unavailable, a repeat Xpert MTB/RIF® assay should be performed by the study laboratory to confirm eligibility before recruitment. The patient should be aged ≥ 18 years on the day of providing informed consent. The patient has a body weight in light clothing and without shoes of at least 35kg. Female patients of child-bearing potential must have a negative urine or serum pregnancy test ≤ 7 days prior to screening, and consent to practice an effective method of contraception until completion of therapy. The patient must have a verifiable residence location and telephone number that is accessible if necessary for contact during follow-up. Exclusion Criteria: Patients for whom one of the following criteria is met will be excluded from the trial: There is concern about any circumstances that raise concern about free, informed consent to study participation. The patient's pre-screening or screening Xpert MTB/RIF® assay result is "negative","trace", or "very low" positive. At least one M tuberculosis isolate, either cultured or detected through molecular assays from sputum obtained from the patient prior to treatment initiation is found to be resistant to one or more of: rifampicin, isoniazid, pyrazinamide, ethambutol, or fluoroquinolones (late exclusion). The patient is in poor general condition where delay in treatment cannot be tolerated, or death within three months is likely, as assessed by the investigator. The patient had a nose/throat swab which was positive for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2), on Polymerase Chain Reaction (PCR) or a rapid diagnostic test ≤ 14 days preceding study recruitment. The patient is pregnant or breast-feeding (female patients only). The patient is unable to take oral medications. The patient has received any investigational drug in the past three months. The patient has received more than five days of treatment directed against active tuberculosis ≤ 6 months preceding initiation of study drugs. The patient has known intolerance to any of the study drugs, or conditions for which they are contra-indicated. The patient is unwilling, or unable to adhere to requirements regarding restricted use of other medications during the study. Restricted medications will include medications which prolong the QTc interval, and CYP450 inhibitors or inducers. The patient is due to initiate, or requires continuation of, non-efavirenz, non-dolutegravir-based anti-retroviral therapy for HIV infection. The patient has decompensated liver disease and/or aminotransaminases >3x upper limit of normal (ULN), serum total bilirubin level >1.5x ULN or serum/plasma creatinine level >x2 ULN. The patient has a baseline QTc interval of >450ms. The patient is being, or about to be, treated for malaria. The patient has other medical conditions that, in the investigator's judgement, make study participation not in the individual's best interest.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Stellah Mpagama, PhD
Phone
+255754860576
Email
sempagama@yahoo.com
First Name & Middle Initial & Last Name or Official Title & Degree
Alphonce Liyoyo, M.D
Phone
+255767134567
Email
liyoyo2010@gmail.com
Facility Information:
Facility Name
Kibong'oto Infectious Diseases Hospital
City
Moshi
State/Province
Kilimanjaro
ZIP/Postal Code
25401
Country
Tanzania
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter Mbelele, M.D. PhD
Phone
255767902477
Email
mbelelepeter@yahoo.com
First Name & Middle Initial & Last Name & Degree
Bibie Said, M.D.MSc
Phone
255718762991
Email
bibiesd90@gmail.com

12. IPD Sharing Statement

Citations:
Citation
World Health Organization. Global Tuberculosis Report 2021. World Health Organisation 2021.https://www.who.int/publications/i/item/9789240037021
Results Reference
background
Citation
World Health Organisation. WHO End TB Strategy: Global strategy and targets for tuberculosis prevention, care and control after 2015. World Health Organization 2021. https://www.who.int/tb/strategy/End_TB_Strategy.pdf
Results Reference
background
PubMed Identifier
34986295
Citation
Pai M, Kasaeva T, Swaminathan S. Covid-19's Devastating Effect on Tuberculosis Care - A Path to Recovery. N Engl J Med. 2022 Apr 21;386(16):1490-1493. doi: 10.1056/NEJMp2118145. Epub 2022 Jan 5. No abstract available.
Results Reference
background
PubMed Identifier
25654354
Citation
Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE; PanACEA Consortium. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. Am J Respir Crit Care Med. 2015 May 1;191(9):1058-65. doi: 10.1164/rccm.201407-1264OC.
Results Reference
background
PubMed Identifier
33542056
Citation
Te Brake LHM, de Jager V, Narunsky K, Vanker N, Svensson EM, Phillips PPJ, Gillespie SH, Heinrich N, Hoelscher M, Dawson R, Diacon AH, Aarnoutse RE, Boeree MJ; PanACEA Consortium. Increased bactericidal activity but dose-limiting intolerability at 50 mg.kg-1 rifampicin. Eur Respir J. 2021 Jul 8;58(1):2000955. doi: 10.1183/13993003.00955-2020. Print 2021 Jul.
Results Reference
background
PubMed Identifier
28100438
Citation
Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PPJ, Hoelscher M; PanACEA consortium. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis. 2017 Jan;17(1):39-49. doi: 10.1016/S1473-3099(16)30274-2. Epub 2016 Oct 26.
Results Reference
background
PubMed Identifier
33951360
Citation
Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE; AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021 May 6;384(18):1705-1718. doi: 10.1056/NEJMoa2033400.
Results Reference
background
Citation
World Health Organization. WHO consolidated guidelines on tuberculosis Module 4: Drug-susceptible tuberculosis treatment. World Health Organization 2022 https://www.who.int/publications/i/item/9789240048126
Results Reference
background

Learn more about this trial

A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis

We'll reach out to this number within 24 hrs